We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
EVALUATE THE CA125 FOR DISCRIMINATE BETWEEN EPITHELIAL OVARIAN CANCER (EOC) AND ENDOMETRIOSIS, OVARIAN CYST DEPENDING ON PSA FUCOSYLATION BY USING NANO-LECTIN IMMUNOASSAY.
- Authors
Ali, Aamer M.; Abdul-Rasheed, Omar F.; Qudir, Hala Abdul
- Abstract
The objective was to evaluate the CA125 for discriminate between epithelial ovarian cancer (EOC) and benign disease endometriosis and ovarian cyst depend on the variations in CA125 glucosylation (GlcNAc carbohydrates) by using macrophage galactose-type lectin (MGL). The new method lectin-immunoassay was established for the investigation of CA125 glucosylation by measuring the fluorescence of Eu(III)-chelate-doped nanoparticles by microplate flourometer. To the identification of GlcNAc carbohydrates on CA125 surface, the lectin-immunoassays using CA125 specific monoclonal antibody as a capture and MGL coupled with Eu(III)-chelate-labeled nanoparticles using as probe for detecting CA125. This method compared with conventional immunoassay ELISA. The concentration of antigen cancer 125 CA125 was obtained from the patients of the endometriosis, ovarian cyst and the epithelial ovarian cancer measured by the conventional immunoassay ELISA were detected a statistically significant increase (p< 0.001) with compared to the healthy control. Also in the same method, the compared CA125 levels between benign conditions of endometriosis, ovarian cyst and epithelial ovarian cancer, it was detected a statistically significant (p< 0.001) and between the same group benign conditions endometriosis with ovarian cyst also statistically significant (p= 0.005). This method depends on the immune attachment in the epitope of the secondary monoclonal antibody with tumor marker as antigen. While, new method was applied the nanoparticle-Eu dopedlectin-immunoassay, it were shown a statistically significant (p< 0.001), when compared to the epithelial ovarian cancer with endometriosis, ovarian cyst and healthy control samples. The nanoparticle-based MGL-immunoassay, this method was discriminated the CA125 sources from epithelial ovarian cancer and endometriosis. It was detected a statistically non-significant the P value were (p = 0.964) for endometriosis and (p = 0.056) for ovarian cyst when compared with healthy controls.
- Subjects
OVARIAN cancer treatment; OVARIAN cancer patients; ENDOMETRIOSIS; OVARIAN cysts; FUCOSYLATION
- Publication
Biochemical & Cellular Archives, 2020, Vol 20, Issue 2, p6305
- ISSN
0972-5075
- Publication type
Article